Minerva announced the presentation of a poster at the Congress of the Schizophrenia International Research Society. Findings to be presented in the poster demonstrate that administration of roluperidone increased BDNF release by astrocytes and hippocampal neurons obtained from the cerebral cortex of newborn rats, as well as the release of GDNF in cultured astrocytes. Furthermore, data showed that roluperidone enhanced BDNF gene expression at drug concentrations similar to those observed in humans at tested doses. Based on these results, researchers suggested that the effect of roluperidone on BDNF and GDNF may indicate the potential of this investigational compound for disease modification and improved neuroplasticity, in addition to its observed effects on the sigma and serotoninergic 5-HT neurotransmitter pathways.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.